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PET Positron Emission Tomography 
 
Abstract 
Desmoplastic small round cell tumor is a rare malignancy most often seen in the abdomen or 
pelvis of young men.  Unfortunately, this disease is usually metastatic at diagnosis and has 
dismal outcomes.  It appears that isolated, paratesticular desmoplastic small round cell tumors 
have a markedly better outcome than the classic abdominal or pelvic location.  We 
hypothesize this is due to earlier detection and the relative ease of surgical resection.  We 
review the literature and describe a case of isolated paratesticular desmoplastic small round 
cell tumor in a 14-year-old male successfully treated with surgical resection, chemotherapy 
and adjuvant radiation. 
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Introduction 
Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive malignancy 
initially described by Gerald and Rosai in 1989 and most often seen in adolescent and young 
adult patients
1,2
.  Histologically, it consists of small round blue cells with a desmoplastic 
reaction.  The immunohistochemical profile demonstrates reactivity for cytokeratin, EMA, 
vimentin and desmin
1
.  Fusion of the EWSR1 and WT1 genes is diagnostic for DSRCT
2
. 
Patients with DSRCT are usually between 5 and 30 years of age.  Males and older 
adolescents are more often affected
2,3
.  A review of pediatric SEER data found 95 reported 
cases in patients 0-21 years of age between 1991 and 2011
3
 .   
DSRCT is most frequently found on abdominal or pelvic serosal surfaces though 
many other locations are reported
4
.  The abdominal or pelvic location can allow the tumor to 
grow for some time before causing symptoms.  When symptoms are present, they are 
generally vague such as weight loss, abdominal fullness and abdominal pain.  Therefore, 
DSRCT is often not diagnosed until the disease burden is large and/or there is metastatic 
disease.  In the SEER database, only 20% of patients had localized disease at presentation
3
. 
The outcomes for DSRCT are quite poor with only 15-30% overall survival at 5 
years
2,3
.  A multi-modal approach to DSRCT therapy is recommended, especially for 
metastatic disease.  Treatment is not standardized but generally includes local control with 
surgical resection and/or radiation along with multiagent chemotherapy
2,5
.  There are reports 
of hyperthermic intraperitoneal radiation and high dose chemotherapy followed by 
autologous stem cell transplant but neither therapy has demonstrated a definitive survival 
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benefit
2,5-7
.  We present a case of a successfully treated isolated paratesticular DSRCT and 
review the literature. 
Case Description 
Our patient was a healthy 14-year-old male when he presented to the pediatric surgery 
clinic with an approximately 1 month history of a left groin bulge.  He had no complaints of 
fevers, weight loss or pain.  He was diagnosed with an apparent inguinal hernia and 
scheduled for surgical repair.  In the operating room, he was discovered to have a multi-
lobulated paratesticular mass.  Frozen section revealed a small round blue cell tumor and he 
underwent gross total resection of the mass with left orchiectomy.   
Pathology showed a malignant small round blue cell tumor with islands of poorly 
differentiated cells, areas of necrosis and areas of brisk mitotic activity.  The tumor was 
diffusely positive for NSE and desmin with focally positivity for EMA and pancytokeratin.  
Myogenin, CD99, CD3, CD45, CD20 and inhibin were all negative.  INI-1 was retained.  
Further molecular testing by PCR demonstrated EWSR1/WT1 chimerism; diagnostic of 
DSRCT.  Cytogenetics demonstrated a gain of chromosome 5, also consistent with DSRCT.  
His testis was negative for disease. 
Our patient was enrolled on a prospective integrative clinical sequencing trial (PEDS-
MIONCOSEQ) and underwent paired tumor/normal whole exome sequencing (WES) and 
tumor transcriptome sequencing (RNA-Seq). Specifics of the sequencing procedure and 
bioinformatics analysis have been previously described
8
.  The study detected the 
characteristic EWSR1-WT1 gene fusion, copy gains in of chr1q, 3, 5, 9, 15 and 21, as well as 
a somatic mutation of MAP3K13 at a low alleic frequency of 5.7%; the significance of which 
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remains unknown in this tumor
9
.  Our patient had microscopic positivity at the tumor margins 
and the remainder of his staging evaluation including abdominal/pelvic laparoscopic 
exploration, CT chest/abdomen/pelvis and PET scan was negative.   
Our patient was then treated with chemotherapy and adjuvant radiation.  His 
chemotherapy was in accordance with Children’s Oncology Group (COG) protocol 
AEWS1031 arm B with vincristine, topotecan, cyclophosphamide, doxorubicin, etoposide 
and ifosfamide.  He received 50.4 Gray of adjuvant radiation to the tumor bed after cycle 6 of 
chemotherapy due to his microscopically positive margins.  He tolerated radiation and all 17 
cycles of chemotherapy without any significant side effects.  At the time of manuscript 
submission he is 24 months from diagnosis and 13 months from completion of chemotherapy 
without evidence of disease. 
Discussion 
Paratesticular DSRCT is rare with only 20 such cases reported in the literature. 
(Review limited to literature with at least an abstract available in English). Like DSRCT in 
general, it is seen in older adolescents and young adults.  The youngest patient previously 
reported in the literature was 17.  Our patient was 14 at the time of diagnosis.  
Paratesticular DSRCT can present with an isolated mass or with metastatic disease.  
Of the 20 reported cases, 12 had localized disease (see Table 1)
4,5,10-16
 and 8 had metastatic 
disease at the time of diagnosis (see Table 2)
10,17-21
.   Most patients presented due to a mass or 
testicular pain.  Our patient presented with a painless mass and his staging evaluation did not 
find any metastatic disease.  
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There is no standardized treatment approach for DSRCT but surgery is the preferred 
means of local control
2
.  All of the reported paratesticular DSRCT patients underwent 
surgical resection, often with orchiectomy.  The ubiquity of surgery is likely because the 
paratesticular location makes surgery feasible sooner after diagnosis and less morbid.  Our 
patient underwent a gross total excision with high inguinal orchiectomy. 
Radiation therapy is also commonly used for local control in DSRCT, especially for 
those unable to undergo surgical resection
2
.  The dose and field of radiation administered 
varies
2,4,5
.  Interestingly, none of the reported patients with paratesticular DSRCT received 
radiation therapy.  We opted to give our patient adjuvant local radiation therapy due to his 
microscopically positive margins.  In our review, the post-surgical margin status was not 
addressed for any of the cases. 
Multiagent chemotherapy is considered standard therapy for DSRCT in the 
neoadjuvant or adjuvant setting.  A variety of chemotherapy regimens have been used and 
most are similar to approaches used for Ewing sarcoma
2
.  Based on the limited literature for 
DSRCT treatment, we chose the most recent pediatric Ewing protocol, the COG protocol 
AEWS1031.   
Despite multimodal therapy, patients with DSRCT overall have very poor survival 
rates of 15-30% at 5 years
2,3
.  Patients with paratesticular DSRCT appear to have far better 
outcomes. Out of the 20 previously reported cases of paratesticular DSRCT, 17 had follow up 
data available.  Of those 17, 10 (~60%) were alive without evidence of disease between 6 and 
120 months off therapy.  When only patients with metastatic disease are considered, 2 of 6 
(33%) were alive 6 to 30 months after diagnosis.  However, for those patients with isolated 
  
 
This article is protected by copyright. All rights reserved. 
 
paratesticular disease, 8 of 10 (80%) were alive without evidence of disease 33 to 120 months 
after diagnosis.  One patient was alive with disease 12 months after diagnosis.  This review 
suggests that the survival rate for isolated paratesticular disease is better than metastatic 
paratesticular disease and the outcomes in paratesticular location in general are much better 
than the DSRCT outcomes overall.  Accordingly, our patient is alive and well without 
evidence of disease 24 months after diagnosis. 
The dramatically improved survival of isolated paratesticular DSRCT compared to 
DSRCT overall is likely due to its location.  The location of the mass renders itself to early 
detection by patients which leads to earlier medical intervention.  The paratesticular location 
also improves the feasibility of complete surgical excision.   
It is unclear if paratesticular DSRCT tumors are biologically distinct from the more 
typical, widely metastatic DSRCT.  While the tumor sequencing did not show any actionable 
targets in our case, ongoing studies will hopefully identify novel targeted therapies that are 
less toxic and more effective for this disease.     
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TABLE 1 Isolated Paratesticular Desmoplastic Small Round Cell Tumors Reported in the 
Literature 
First Author Number 
of 
Patients1 
Patient 
Age 
(Years) 
Treatment Patient Outcome at Time of 
Report 
Bisogno 1 17 Complete surgical resection 
with orchiectomy, 
chemotherapy (VCR, D, I) 
NED 63 months after diagnosis 
Cummings 4 17 Orchiectomy2, chemotherapy 
(CDDP, D, CPM)  
Lost to follow up 
  28 Orchiectomy2 chemotherapy3  Relapse in cervical lymph nodes 
at 7 months after diagnosis, 
DOD 16 months after diagnosis 
  28 Orchiectomy2, chemotherapy3  Relapse with pulmonary disease 
at 24 months after diagnosis, 
NED at 36 months after 
diagnosis  
  37 Orchiectomy2 Relapse in the retroperitoneum 
36 months after diagnosis, lost 
to follow up 
Farhat 1 ? Orchiectomy2, chemotherapy 
(CDDP, Epi, CPM, VP16)  
NED 32 months after relapse 
(unclear if metastatic disease at 
diagnosis, widespread disease 
at relapse) 
Furman 1 21 Surgical resection2, 
chemotherapy (Carbo, I, 
VP16, VCR, CPM, A)  
NED 33 months after diagnosis 
Garcia-Gonzalez 1 23 Surgical resection2, 
chemotherapy (Initial:  MTX, 
Dacarb, CPM, D, VCR; 
Subsequent: D, VCR, A, CPM)  
NED 72 months after diagnosis 
Ordonez 1 28 Orchiectomy2, chemotherapy 
(CDDP, VP16) 
AWD: regional metastatic 
disease 12 months after 
diagnosis (unclear if metastatic 
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disease at diagnosis) 
Roganovich 1 17 Complete surgical resection, 
chemotherapy (I, D, VCR) 
NED 60 months years from 
diagnosis 
Saab 1 19 Complete surgical resection, 
chemotherapy (Carbo, VCR, A, 
CPM, I, VP-16) 
NED at 120 months from 
diagnosis 
Sha 1 27 Orchiectomy2, chemotherapy 
(CDDP, VP16, I, Epi) 
NED 36 months from diagnosis 
NED = no evidence of disease DOD = dead of disease AWD = alive with disease A = 
doxorubicin Carbo = carboplatin  
CDDP = cisplatin CPM = cyclophosphamide D = dactinomycin Dacarb = dacarbizine Epi = 
epirubicin I = ifosfamide MTX = methotrexate VCR = vincristine VP16 = etoposide 
1
only 
newly reported patients are included 
2
unclear if complete surgical resection 
3
unclear which 
chemotherapy used and if it was given up front, at relapse or both 
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TABLE 2 Metastatic Paratesticular Desmoplastic Small Round Cell Tumors Reported in the 
Literature 
First Author Number of 
Patients1 
Patient Age 
(Years) 
Location of 
Metastasis (at 
diagnosis) 
Treatment Patient Outcome 
at Time of Report 
Cliteur 1 32 Abdomen Orchiectomy, 
chemotherapy 
(VCR, VP16, I, A)  
DOD 24 months 
after diagnosis 
Cummings 2 32 Retroperitoneal 
mass 
Orchiectomy Lost to follow up 
  26 Lungs, lymph 
nodes 
Orchiectomy, 
chemotherapy2, 
bone marrow 
transplant 
NED 30 months 
after diagnosis  
Prat 1 22 Lungs, lymph 
nodes (regional 
and distant) 
Orchiectomy, 
chemotherapy2 
DOD 17 months 
after diagnosis 
Rais 1 27 Abdomen Surgical resection, 
chemotherapy2 
NED 6 months after 
diagnosis 
Thuret 1 34 Retroperitoneal Orchiectomy, 
chemotherapy2 
? 
Yue 2 25 and 35 Abdominal and 
retroperitoneal 
One received 
orchiectomy, 
hepatic artery 
embolization, and 
chemotherapy 
(CPM, Pir, Vind, 
Dacarb), the other 
received 
chemotherapy 
alone (CPM, Epi, 
Vinp) (unclear 
which patient 
received surgery) 
Unclear but 
appears they both 
are DOD 
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NED = no evidence of disease DOD = dead of disease AWD = alive with disease A = 
doxorubicin CDDP = cisplatin  
CPM = cyclophosphamide Dacarb = dacarbazine Epi = epirubicin I = ifosfamide Pir = 
pirarubicin VCR = vincristine Vind = vindesine  
Vinp = vinpocetine VP16 = etoposide 
1
only newly reported patients are included 
2
unclear 
which chemotherapy used  
 
 
 
 
